|
|
||||||||
Department of Genomics, Life and Brain Center, University of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
(Requests for offprints should be addressed to A M Hillmer; Email: axel.hillmer{at}uni-bonn.de)
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
-dihydrotestosterone (DHT), the conformation of AR alters and it binds as a homodimer to androgen response elements, executing its function as a transcription factor (Lee & Chang 2003). Given its central function in androgen-related pathways, genetic variation in the AR gene has been tested for association with a variety of common human traits (Quigley et al. 1995, Edwards et al. 1999, Hsing et al. 2000, Avila et al. 2001, Ellis et al. 2001, Chang et al. 2002, Aschim et al. 2004, Ferlin et al. 2004, Ruhayel et al. 2004, Zeegers et al. 2004, Hillmer et al. 2005, Sasaki et al. 2005, Cox et al. 2006, Lundin et al. 2006). The most widely tested variants are two repeat sequences, CAG and GGN repeats, in the coding region of AR that encode variable lengths of polyglutamine (polyQ) and polyglycine (polyG) tracts in the N-terminal part of the protein. The effect of repeat lengths on receptor function has been investigated for both of these repeats. A large body of evidence suggests that a long CAG repeat results in reduced AR transactivity (Mhatre et al. 1993, Chamberlain et al. 1994, Kazemi-Esfarjani et al. 1995, Gao et al. 1996, Nakajima et al. 1996, Buchanan et al. 2004, Wang et al. 2004). Fewer studies have been performed for the GGN repeat. The GGN-encoded polyG tract is located in one of the two N-terminal transactivating domains of the AR protein. In accordance with this, functional data suggest an impact of the GGN repeat on transactivating activity of AR (Gao et al. 1996, Ding et al. 2005, Werner et al. 2006). While these studies have analyzed several repeat lengths, they did not compare the functional properties of the alleles of 23 and 24 glycine repeats which are the most common repeats found in the European population and which have been reported to confer opposite effects on the development of human traits (Ellis et al. 2001, Aschim et al. 2004, Ferlin et al. 2004, Hillmer et al. 2005). Recently, Lundin et al.(2007) reported the first functional comparison of AR with polyG23 and polyG24 using a prostate-specific antigen promoter-driven reporter gene in COS-1 cells. PolyG23 showed higher transactivating activity than polyG24 at various DHT and R1881 concentrations which was not due to higher protein concentrations.
In the present study, we analyzed the transactivating activity of AR containing the two most common repeat lengths (23 and 24 repeats) as well as two extreme repeat lengths 10 and 27 repeats. We used a GRE2TATA promoter-driven reporter gene assay in HeLa cells as an experimental model. To further understand the cause of functional differences, we quantified AR protein and AR messenger and determined per-protein activity.
| Results |
|---|
|
|
|---|
|
|
Is the higher protein quantity of AR with longer repeats due to higher transcript levels? To address this question, AR messenger of HeLa transfection experiments was quantified. There was no clear correlation between repeat length and AR transcript quantity in the presence of DHT (Fig. 3
). However, polyG10 and polyG27 demonstrated lower and higher messenger concentrations respectively. Transcript levels were clearly higher in the absence of hormone than in the presence of hormone, whereby shorter repeats show lower AR transcript levels than longer repeats.
To test whether polyG specific differences in AR quantity are due to differences in protein stability, translation of transfected HeLa cells was inhibited by cycloheximide (CHX) and AR protein was quantified by ELISA at different time points. By inhibition of translation for 8 h, AR quantity declined, whereas ß-actin concentration did not change significantly (Fig. 4A
). Although there was a significant effect of different AR polyG lengths on AR quantity after 2.5 h of translation inhibition, no consistent differences over three inhibition times were observed (Fig. 4B
).
|
| Discussion |
|---|
|
|
|---|
|
In the present study, we have focused on the two most common alleles of the GGN repeat. However, less common GGN alleles might also contribute to disease susceptibility as suggested for other rare sequence variations contributing to complex traits (Pritchard & Cox 2002, Cohen et al. 2004). Our data imply that rare GGN alleles can have stronger effects on AR function. This may result in higher penetrance with regard to expression of disease.
Since the CAG repeat also affects AR function (Mhatre et al. 1993, Chamberlain et al. 1994, Kazemi-Esfarjani et al. 1995, Gao et al. 1996, Nakajima et al. 1996, Buchanan et al. 2004, Wang et al. 2004), the combination of certain CAG and GGN alleles might have additive effects as suggested by the detection of functional differences between five analyzed CAG/GGN combinations (Gao et al. 1996). In whites, there is no significant linkage disequilibrium between the two repeats (Kittles et al. 2001), resulting in a variety of haplotypes with potential differences in AR function. The variance of the allelic distribution across populations (Kittles et al. 2001) may contribute to population-specific differences in the susceptibility for associated traits.
As androgens mediate a wide range of developmental and physiological responses through AR, (Lee & Chang 2003), it is conceivable that variability in AR can have an impact on a set of human traits. It has been proposed that slight changes in AR function caused by different GGN alleles may predispose to the development of congenital abnormalities of male genital organs (Aschim et al. 2004). Further, certain CAG/GGN haplotypes have been suggested to increase susceptibility to infertility (Ferlin et al. 2004), and an association between the GGN repeat and semen volume has been reported (Lundin et al. 2006). A decreased risk of breast cancer has been described for women with long GGN alleles (Suter et al. 2003), whereas other studies could not detect association (Dunning et al. 1999, Kadouri et al. 2001). Shorter GGN alleles have been associated with an increased risk of prostate cancer (Hsing et al. 2000, Chang et al. 2002), while longer alleles have been associated with endometrial cancer (Sasaki et al. 2005) which would be in accordance with the differing effects of androgens on the endometrium and the prostate (androgens exert an inhibitory effect on endometrial cell proliferation, whereas they have a mitogenic effect in the prostate). However, the association findings with prostate cancer remain controversial and no effect was shown in a large meta-analysis (Zeegers et al. 2004). For the combination of short CAG and GGN repeats and the GGN23 allele respectively, association with androgenetic alopecia has been reported (Ellis et al. 2001, Hillmer et al. 2005). Our finding of a functional difference between the two most common alleles of the GGN repeat supports a direct role of the repeat in the development of human traits. The unraveling of tissue-specific consequences of different GGN alleles should help to understand the pathophysiology of associated traits.
| Materials and methods |
|---|
|
|
|---|
EDTA-anticoagulated venous blood samples were collected from 188 German male blood donors from the blood transfusion center of the University Hospital Bonn, and lymphocyte DNA was isolated by salting out with saturated NaCl solution (Miller et al. 1988). The study was approved by the ethics committee of the University of Bonn, and informed consent was obtained from all participants. Genotyping of the GGN repeat of AR was performed as described elsewhere (Hillmer et al. 2005).
Plasmids
AR expression plasmids: human AR GGN alleles of 10, 23, 24, and 27 repeats were amplified from genomic DNA by PCR using GGC-clone-F primer CAACTTTC-CACTGGCTCTGG and GGC-clone-R primer GGA-TAGGGCACTCTGCTCAC. PCR fragments were subcloned in pCR2.1 (Invitrogen) according to standard protocol and verified by sequencing. pSG5-AR expression plasmid was kindly provided by Dr John Isaacs (Cellular and Molecular Medicine, Baltimore, MD, USA). Subcloned GGN alleles of 10, 23, 24, and 27 repeats (GGN10: (GGT)3GGG(GGT)2GGC4, GGN23: (GGT)3GGG(GGT)2GGC17, GGN24: (GGT)3-GGG(GGT)2GGC18, and GGN27: (GGT)3GGG(GGT)3-GGC20) were cloned in pSG5-AR by sequential restriction with CpoI and KpnI (Fermentas, St Leon-Rot, Germany) flanking the GGN repeat. Ligation was performed by the use of the Rapid DNA Ligation Kit (Roche Molecular Biochemicals) according to the manufacturers recommendations. Transfers were verified by sequencing and restriction with CpoI/KpnI. Restriction fragments were analyzed on a 3% agarose gel. pSG5-AR has 22 CAG repeats.
Androgen responsive firefly luciferase reporter plasmid pGRE2-TATA-Luc was kindly provided by Dr Rainer B Lanz (Department of Molecular and Cellular Biology, Baylor College of Medicine, Housten, USA). pGRE2-TATA-Luc contains the firefly luciferase gene and two glucocorticoid (and androgen) responsive elements. This reporter gene construct has been shown to be more androgen responsive than the commonly used mouse mamary tumor virus (MMTV)-Luc reporter system containing another glucocorticoid-responsive elements-harboring promoter (Alléra et al. 1998).
Renilla luciferase plasmid phRL (Promega GmbH) was used for transfection efficiency control, which contains the cytomegalovirus (CMV) immediate-early promoter/enhancer region for strong and constitutive expression of the R. luciferase.
Tissue culture
HeLa cells for real-time PCRs, luciferase experiments, and ELISA were cultured in Dulbeccos modified Eagles medium (DMEM; CAMBREX Bio Science, Verviers, Belgium) with 10% fetal calf serum (Biochrom AG, Berlin, Germany), 1% penicillin/streptomycin (Invitrogen), and 1 x Amphotericin B (Roche Molecular Biochemicals) at 37 ° C and 5% CO2. A total of 210 000 cells per well were seeded in 12-well culture plates 1 day before transfection. On the day of transfection, cells were 8090% confluent and the medium was replaced by serum-free OptiMEM (Invitrogen). Transfections per well were carried out using 500 ng pSG5-AR, 500 ng pGRE2-TATA-Luc, 12.5 ng phRL, and 3 µ l Lipofectamine2000 (Invitrogen) in OptiMEM according to standard protocol. After 6 h of incubation, the transfection mixture was replaced by DMEM with 10% steroid hormone-stripped fetal calf serum with 1 nM DHT and carrier (ethanol) respectively. Cells were harvested after an additional 21 h of incubation. For each experiment, two transfections of each AR plasmid were incubated with carrier and three transfections were incubated with DHT. For AR stability assays, 250 000 cells were seeded in each well of a 12-well plate. Cells of each well were transfected the following day with 500 ng pSG5-AR and incubated in medium containing 1 nM DHT 6 h after transfection start. Twenty-four hours after transfection start, medium was replaced by medium containing 1 nM DHT and 100 ng/µ l CHX or carrier (H2O) and incubated for 0, 2.5, 5, and 8 h. For every experiment, each AR construct incubated with and without CHX was assayed in triplicate and duplicate respectively. At least three experiments were performed for both protein-and RNA-based assays. Cells were washed with PBS and harvested in 250 µ l passive lysis buffer (Promega) for protein-based assays and in 300 µ l nucleic acid purification lysis solution (Applied Biosystems, Darmstadt, Germany) for real-time PCR.
Luciferase assay
Dual-luciferase Reporter Assay System (Promega) was used to quantify AR-driven reporter gene activity (firefly luciferase) and transfection control (R. luciferase) using 20 µ l cell lysate, 50 µ l luciferase assay reagent II, and 50 µ l Stop&Glo reagent. Luciferase activities were quantified in 96-well plates in a GeniosPro plate reader (TECAN, Crailsheim, Germany). Firefly luciferase activities were corrected for variation in transfection efficiency by the respective R. luciferase activities. Relative luciferase units of polyG23 + DHT were set as 100%.
ELISA
Fifty microliters of transfected HeLa cell extracts in passive lysis buffer (as used for luciferase assays) per well were assayed by ELISA using the NR Sandwich AR kit (Active Motif, Rixensart, Belgium) according to the manufacturers recommendations. Colorimetric quantification was performed in a DYNEX MRX II microplate photometer (DYNEX Technologies, Berlin, Germany) in 96-well plates. For AR quantification in activity assays, optical densities were normalized by R. luciferase luminescence and polyG23 + DHT was set as 100%. For AR quantification in stability assays, optical densities of each AR polyG allele were normalized to their respective optical densities at t = 0. Each AR polG allele at t = 0 was set as 100%.
Real-time PCR
Total RNA was extracted from transfected HeLa cell samples in nucleic acid purification lysis solution (Applied Biosystems) through the use of an ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems). The quality and quantity of the RNA was verified on a NanoDrop ND-1000 spectrophotometer (Peqlab Biotechnologie, Erlangen, Germany). RT-PCR was performed with the SuperScriptIII First-Strand Synthesis SuperMix (Invitrogen) with oligo dT primers. Relative quantifications in real-time experiments were performed in 384-well plates with 100 ng cDNA per well in a total volume of 20 µ l on the ABI Prism 7900HT Fast Real-Time PCR System (Applied Biosystems) using the TaqMan Gene Expression Assay (Applied Biosystems) for AR (Hs00171172_m1) and the pre-developed Taq-Man Endogenous Controls Human Cyc (Cyclophilin, 4326316E) and Human B2M (ß-2-microglobulin, 4326319E; Applied Biosystems). Each sample was assayed in triplicate, and normalized by the housekeeping genes cyclophilin and B2M, and CT values were transformed by 100 000 000/2CT. Values were calculated relative to polyG23 + DHT which was set as 100%.
SDSPAGE and western blot
SDSPAGE was performed according to standard protocol (Sambrook & Russel 2001). In brief, 40 µ l pooled cell extract (triplicates and duplicates were pooled) were mixed with 20 µ l 3 x sample buffer. The volume of 40 µ l were loaded on 10% polyacrylamide gels and separated by electrophoresis. Proteins were transferred on polyvinyldifluoride membranes by the semi-dry blotter system (Biometra, Göttingen, Germany). Membranes were stained with ponceau for 2 min and blocked with 5% nonfat milk powder in PBST (phosphate buffered saline containing 0.2% Tween) for 1 h. Rabbit anti-AR antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti-ß-actin antibody (SigmaAldrich) were used for incubation in 1:500 and 1:15 000 dilutions in 5% nonfat milk PBST for 1 h. Membranes were washed thrice for 5 min with PBST and were incubated with 1:30 000 horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies (Jackson ImmunoResearch Laboratories, Suffolk, UK) respectively in 5% nonfat milk PBST for 1 h. Membranes were washed thrice for 20 min in PBST and assayed for peroxidase activity using SuperSignal West Dura (Pierce) and autoradiography.
Statistical analysis
The statistical analysis consisted of the non-parametric KruskalWallis ANOVA on ranks. P values were judged significant at P < 0.05.
| Acknowledgements |
|---|
| References |
|---|
|
|
|---|
Aschim EL, Nordenskjold A, Giwercman A, Lundin KB, Ruhayel Y, Haugen TB, Grotmol T & Giwercman YL 2004 Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene. Journal of Clinical Endocrinology and Metabolism 89 51055109.
Avila DM, Zoppi S & McPhaul MJ 2001 The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 76 135142.[CrossRef][ISI][Medline]
Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA et al. 2004 Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics 13 16771692.
Chamberlain NL, Driver ED & Miesfeld RL 1994 The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research 22 31813186.
Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM et al. 2002 Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Human Genetics 110 122129.[CrossRef][ISI][Medline]
Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R & Hobbs HH 2004 Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305 869872.
Cox DG, Blanche H, Pearce CL, Calle EE, Colditz GA, Pike MC, Albanes D, Allen NE, Amiano P, Berglund G et al. 2006 A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Research 8 R54.[CrossRef][Medline]
Ding D, Xu L, Menon M, Reddy GP & Barrack ER 2005 Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 62 133139.[CrossRef][ISI][Medline]
Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healey CS, Smith N, Pharoah PD, Luben RN, Easton DF et al. 1999 No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 20 21312135.
Edwards SM, Badzioch MD, Minter R, Hamoudi R, Collins N, Ardern-Jones A, Dowe A, Osborne S, Kelly J, Shearer R et al. 1999 Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. International Journal of Cancer 84 458465.[CrossRef][ISI][Medline]
Ellis JA, Stebbing M & Harrap SB 2001 Polymorphism of the androgen receptor gene is associated with male pattern baldness. Journal of Investigative Dermatology 116 452455.[CrossRef][ISI][Medline]
Ferlin A, Bartoloni L, Rizzo G, Roverato A, Garolla A & Foresta C 2004 Androgen receptor gene CAG and GGC repeat lengths in idiopathic male infertility. Molecular Human Reproduction 10 417421.
Gao T, Marcelli M & McPhaul MJ 1996 Transcriptional activation and transient expression of the human androgen receptor. Journal of Steroid Biochemistry and Molecular Biology 59 920.[CrossRef][ISI][Medline]
Hillmer AM, Hanneken S, Ritzmann S, Becker T, Freudenberg J, Brockschmidt FF, Flaquer A, Freudenberg-Hua Y, Jamra RA, Metzen C et al. 2005 Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. American Journal of Human Genetics 77 140148.[CrossRef][ISI][Medline]
Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J & Chang C 2000 Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Research 60 51115116.
Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T & Eeles RA 2001 CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. British Journal of Cancer 85 3640.[CrossRef][ISI][Medline]
Kazemi-Esfarjani P, Trifiro MA & Pinsky L 1995 Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Human Molecular Genetics 4 523527.
Kittles RA, Young D, Weinrich S, Hudson J, Argyropoulos G, Ukoli F, Adams-Campbell L & Dunston GM 2001 Extent of linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in human populations: implications for prostate cancer risk. Human Genetics 109 253261.[CrossRef][ISI][Medline]
Lander ES 1996 The new genomics: global views of biology. Science 274 536539.
Lee HJ & Chang C 2003 Recent advances in androgen receptor action. Cellular and Molecular Life Sciences 60 16131622.[CrossRef][ISI][Medline]
Lumbroso R, Beitel LK, Vasiliou DM, Trifiro MA & Pinsky L 1997 Codon-usage variants in the polymorphic (GGN)n trinucleotide repeat of the human androgen receptor gene. Human Genetics 101 4346.[CrossRef][ISI][Medline]
Lundin KB, Giwercman YL, Rylander L, Hagmar L & Giwercman A 2006 Androgen receptor gene GGN repeat length and reproductive characteristics in young Swedish men. European Journal of Endocrinology 155 347354.
Lundin KB, Giwercman A, Dizeyi N & Giwercman YL 2007 Functional in vitro characterisation of the androgen receptor GGN polymorphism. Molecular and Cellular Endocrinology 264 184187.[CrossRef][ISI][Medline]
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835839.[CrossRef][ISI][Medline]
Mhatre AN, Trifiro MA, Kaufman M, Kazemi-Esfarjani P, Figlewicz D, Rouleau G & Pinsky L 1993 Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nature Genetics 5 184188.[CrossRef][ISI][Medline]
Miller SA, Dykes DD & Polesky HF 1988 A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 16 1215.
Nakajima H, Kimura F, Nakagawa T, Furutama D, Shinoda K, Shimizu A & Ohsawa N 1996 Transcriptional activation by the androgen receptor in X-linked spinal and bulbar muscular atrophy. Journal of the Neurological Sciences 142 1216.[CrossRef][ISI][Medline]
Pritchard JK & Cox NJ 2002 The allelic architecture of human disease genes: common diseasecommon variant... or not? Human Molecular Genetics 11 24172423.
Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM & French FS 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrine Reviews 16 271321.[CrossRef][ISI][Medline]
Ruhayel Y, Lundin K, Giwercman Y, Hallden C, Willen M & Giwercman A 2004 Androgen receptor gene GGN and CAG polymorphisms among severely oligozoospermic and azoospermic Swedish men. Human Reproduction 19 20762083.
Sambrook J & Russel DW 2001 In Molecular Cloning: a Laboratory Manual, 3rd edn, pp A8.40A8.45. Ed J Argentine. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
Sasaki M, Karube A, Karube Y, Watari M, Sakuragi N, Fujimoto S & Dahiya R 2005 GGC and StuI polymorphism on the androgen receptor gene in endometrial cancer patients. Biochemical and Biophysical Research Communications 329 100104.[CrossRef][ISI][Medline]
Suter NM, Malone KE, Daling JR, Doody DR & Ostrander EA 2003 Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiology, Biomarkers and Prevention 12 127135.
Wang Q, Udayakumar TS, Vasaitis TS, Brodie AM & Fondell JD 2004 Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells. Journal of Biological Chemistry 279 1731917328.
Werner R, Holterhus PM, Binder G, Schwarz HP, Morlot M, Struve D, Marschke C & Hiort O 2006 The A645D mutation in the hinge region of the human androgen receptor (AR) gene modulates AR activity, depending on the context of the polymorphic glutamine and glycine repeats. Journal of Clinical Endocrinology and Metabolism 91 35153520.
Zeegers MP, Kiemeney LA, Nieder AM & Ostrer H 2004 How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiology, Biomarkers and Prevention 13 17651771.
Received in final form 18 April 2007
Accepted 18 April 2007
Made available online as an Accepted Preprint 2 May 2007
This article has been cited by other articles:
![]() |
K. Usdin The biological effects of simple tandem repeats: Lessons from the repeat expansion diseases Genome Res., July 1, 2008; 18(7): 1011 - 1019. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |